ALPHA-SULFO-OMEGA-(DODECYLOXY)POLY(OXYETHYLENE) AMMONIUM SALT

General Information

MaintermALPHA-SULFO-OMEGA-(DODECYLOXY)POLY(OXYETHYLENE) AMMONIUM SALT
CAS Reg.No.(or other ID)32612-48-9
Regnum 175.105
178.3400

From www.fda.gov

Computed Descriptors

Download SDF
2D Structure
CID61913
IUPAC Nameazane;2-dodecoxyethyl hydrogen sulfate
InChIInChI=1S/C14H30O5S.H3N/c1-2-3-4-5-6-7-8-9-10-11-12-18-13-14-19-20(15,16)17;/h2-14H2,1H3,(H,15,16,17);1H3
InChI KeyOPVLOHUACNWTQT-UHFFFAOYSA-N
Canonical SMILESCCCCCCCCCCCCOCCOS(=O)(=O)O.N
Molecular FormulaC14H33NO5S

From Pubchem

Computed Properties

Property Name Property Value
Molecular Weight327.48
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count6
Rotatable Bond Count15
Complexity284.0
CACTVS Substructure Key Fingerprint A A A D c f B y O A B A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A G g A Q C A A A C A C g g A I C A A A A B I A A A A A A A D A A A A A A A A A A A A A A A A A B A A I A A A A C A A A E A A A C A A G A w K A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A = =
Topological Polar Surface Area82.2
Monoisotopic Mass327.208
Exact Mass327.208
Compound Is CanonicalizedTrue
Formal Charge0
Heavy Atom Count21
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Isotope Atom Count0
Covalently-Bonded Unit Count2

From Pubchem

ADMET Predicted Profile --- Classification

Model Result Probability
Absorption
Blood-Brain BarrierBBB+0.9182
Human Intestinal AbsorptionHIA+0.8992
Caco-2 PermeabilityCaco2-0.6120
P-glycoprotein SubstrateNon-substrate0.5432
P-glycoprotein InhibitorNon-inhibitor0.7061
Non-inhibitor0.9710
Renal Organic Cation TransporterNon-inhibitor0.9073
Distribution
Subcellular localizationMitochondria0.4069
Metabolism
CYP450 2C9 SubstrateNon-substrate0.8733
CYP450 2D6 SubstrateNon-substrate0.8287
CYP450 3A4 SubstrateNon-substrate0.5833
CYP450 1A2 InhibitorNon-inhibitor0.8136
CYP450 2C9 InhibitorNon-inhibitor0.8209
CYP450 2D6 InhibitorNon-inhibitor0.8969
CYP450 2C19 InhibitorNon-inhibitor0.7892
CYP450 3A4 InhibitorNon-inhibitor0.9788
CYP Inhibitory PromiscuityLow CYP Inhibitory Promiscuity0.9270
Excretion
Toxicity
Human Ether-a-go-go-Related Gene InhibitionWeak inhibitor0.5536
Non-inhibitor0.5755
AMES ToxicityNon AMES toxic0.7946
CarcinogensCarcinogens 0.5649
Fish ToxicityHigh FHMT0.8840
Tetrahymena Pyriformis ToxicityHigh TPT0.8766
Honey Bee ToxicityHigh HBT0.6413
BiodegradationReady biodegradable0.6261
Acute Oral ToxicityIII0.7087
Carcinogenicity (Three-class)Non-required0.6541

From admetSAR

ADMET Predicted Profile --- Regression

Model Value Unit
Absorption
Aqueous solubility-2.4219LogS
Caco-2 Permeability0.0514LogPapp, cm/s
Distribution
Metabolism
Excretion
Toxicity
Rat Acute Toxicity2.4074LD50, mol/kg
Fish Toxicity1.8626pLC50, mg/L
Tetrahymena Pyriformis Toxicity0.3038pIGC50, ug/L

From admetSAR

Toxicity Profile

Route of ExposureOral ; inhalation ; dermal
Mechanism of ToxicityWhile ammonium laureth sulfate itself is not toxic, it is a nitrosating agent. Nitrosating agents may decompose and/or react to cause nitrosamine contamination. Nitrosamines are produced from secondary amines and amides in the presence of nitrite ions and are believed to be carcinogenic. Once in the body, nitrosamines are activated by cytochrome P-450 enzymes. They are then believed to induce their carcinogenic effects by forming DNA adducts at the N- and O-atoms.
MetabolismNitrosamines can enter the body via ingestion, inhalation, or dermal contact. Once in the body, nitrosamines are metabolized by cytochrome P-450 enzymes, which essentially activates them into carcinogens.
Toxicity Values
Lethal Dose
Carcinogenicity (IARC Classification)Not listed by IARC. Certain nitrosamines are classified by IARC as either probably or possibly carcinogenic to humans (Groups 2A and 2B, respectively).
Minimum Risk Level
Health EffectsAmmonium laureth sulfate itself only causes mild irritation. However, it may react to produce nitrosamines, which are believed to be carcinogenic. (L1888, L1890)
Treatment
Reference
  1. Oyama T, Sugio K, Uramoto H, Iwata T, Onitsuka T, Isse T, Nozoe T, Kagawa N, Yasumoto K, Kawamoto T: Increased cytochrome P450 and aryl hydrocarbon receptor in bronchial epithelium of heavy smokers with non-small cell lung carcinoma carries a poor prognosis. Front Biosci. 2007 May 1;12:4497-503.[17485391 ]
  2. Sasaki S, Sata F, Katoh S, Saijo Y, Nakajima S, Washino N, Konishi K, Ban S, Ishizuka M, Kishi R: Adverse birth outcomes associated with maternal smoking and polymorphisms in the N-Nitrosamine-metabolizing enzyme genes NQO1 and CYP2E1. Am J Epidemiol. 2008 Mar 15;167(6):719-26. doi: 10.1093/aje/kwm360. Epub 2008 Jan 23.[18218609 ]
  3. Drablos F, Feyzi E, Aas PA, Vaagbo CB, Kavli B, Bratlie MS, Pena-Diaz J, Otterlei M, Slupphaug G, Krokan HE: Alkylation damage in DNA and RNA--repair mechanisms and medical significance. DNA Repair (Amst). 2004 Nov 2;3(11):1389-407.[15380096 ]

From T3DB

Taxonomic Classification

KingdomOrganic compounds
SuperclassOrganic acids and derivatives
ClassOrganic sulfuric acids and derivatives
SubclassSulfuric acid esters
Intermediate Tree NodesNot available
Direct ParentSulfuric acid monoesters
Alternative Parents
Molecular FrameworkAliphatic acyclic compounds
SubstituentsAlkyl sulfate - Sulfate-ester - Sulfuric acid monoester - Ether - Dialkyl ether - Organic nitrogen compound - Organic oxygen compound - Organic oxide - Hydrocarbon derivative - Organooxygen compound - Aliphatic acyclic compound
DescriptionThis compound belongs to the class of organic compounds known as sulfuric acid monoesters. These are organic compounds containing the sulfuric acid monoester functional group, with the generic structure ROS(O)(=O)=O, (R=organyl group).

From ClassyFire